Luye Pharma Group Ltd - Asset Resilience Ratio

Latest as of December 2025: 9.15%

Luye Pharma Group Ltd (LUP) has an Asset Resilience Ratio of 9.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€3.00 Billion

≈ $3.51 Billion USD Cash + Short-term Investments

Total Assets

€32.83 Billion

≈ $38.38 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Luye Pharma Group Ltd's Asset Resilience Ratio has changed over time. Check Luye Pharma Group Ltd (LUP) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Luye Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Luye Pharma Group Ltd market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.00 Billion	9.15%
Total Liquid Assets	€3.00 Billion	9.15%

Asset Resilience Insights

Limited Liquidity: Luye Pharma Group Ltd maintains only 9.15% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Luye Pharma Group Ltd Industry Peers by Asset Resilience Ratio

Compare Luye Pharma Group Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd SHG:688621	Drug Manufacturers - Specialty & Generic	2.04%
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	Drug Manufacturers - Specialty & Generic	0.01%
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	Drug Manufacturers - Specialty & Generic	7.85%
Jw Pharmac KO:001060	Drug Manufacturers - Specialty & Generic	3.65%
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Samjin Pharm KO:005500	Drug Manufacturers - Specialty & Generic	0.25%

Annual Asset Resilience Ratio for Luye Pharma Group Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Luye Pharma Group Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	9.15%	€3.00 Billion ≈ $3.51 Billion	€32.83 Billion ≈ $38.38 Billion	+3.86pp
2024-12-31	5.29%	€1.57 Billion ≈ $1.83 Billion	€29.61 Billion ≈ $34.62 Billion	-5.96pp
2023-12-31	11.25%	€2.87 Billion ≈ $3.35 Billion	€25.49 Billion ≈ $29.80 Billion	-2.03pp
2022-12-31	13.28%	€3.22 Billion ≈ $3.77 Billion	€24.25 Billion ≈ $28.35 Billion	-0.32pp
2021-12-31	13.60%	€3.07 Billion ≈ $3.59 Billion	€22.58 Billion ≈ $26.40 Billion	+6.13pp
2020-12-31	7.47%	€1.54 Billion ≈ $1.80 Billion	€20.63 Billion ≈ $24.12 Billion	-7.35pp
2019-12-31	14.82%	€2.86 Billion ≈ $3.35 Billion	€19.31 Billion ≈ $22.58 Billion	-3.36pp
2018-12-31	18.19%	€3.19 Billion ≈ $3.73 Billion	€17.54 Billion ≈ $20.50 Billion	-5.75pp
2017-12-31	23.93%	€2.58 Billion ≈ $3.01 Billion	€10.76 Billion ≈ $12.58 Billion	-1.59pp
2016-12-31	25.52%	€2.35 Billion ≈ $2.75 Billion	€9.21 Billion ≈ $10.76 Billion	--

pp = percentage points

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.05 Billion

€894.77 Million EUR

Market Cap Rank

#8606 Global

#1133 in Germany

Share Price

€0.22

Change (1 day)

+0.00%

52-Week Range

€0.19 - €0.43

All Time High

€0.70